文献
J-GLOBAL ID:201802280865670552
整理番号:18A0259694
プラチナ製剤抵抗性再発卵巣癌の治療のための単剤化学療法へのベバシズマブの追加:AURELIA試験の費用対効果分析【Powered by NICT】
Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial
著者 (6件):
Wysham Weiya Z.
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, United States)
,
Schaffer Elisabeth M.
(Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, United States)
,
Coles Theresa
(Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, United States)
,
Roque Dario R.
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, United States)
,
Wheeler Stephanie B.
(Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, United States)
,
Kim Kenneth H.
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, United States)
資料名:
Gynecologic Oncology
(Gynecologic Oncology)
巻:
145
号:
2
ページ:
340-345
発行年:
2017年
JST資料番号:
E0561C
ISSN:
0090-8258
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)